Clinical trials: Ruxolitinib
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
This phase II trial studies how well ruxolitinib phosphate works in treating patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (aCML).
- Trial name
- NCT02092324
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- OHSU Knight Cancer Institute
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
- Trial name
- MORPHEUS (NCT05696392)
- Testing
- ruxolitinib cream
- Where
- 30 sites in United States
- Volunteers
- 47 people
- Sponsor
- Incyte Corporation
Myelofibrosis
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF).
- Trial name
- NCT01317875
- Testing
- Ruxolitinib
- Where
- 18 sites in United States, Austria and 6 more
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Lichen Sclerosus
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 12 weeks…
- Trial name
- NCT05593445
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 14 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Myelofibrosis
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with…
- Trial name
- NCT02784496
- Testing
- Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
Ruxolitinib in Operable Head and Neck Cancer
The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.
- Trial name
- NCT03153982
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
MPN (Myeloproliferative Neoplasms)
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L.
- Trial name
- NCT01348490
- Testing
- Ruxolitinib
- Where
- 38 sites in United States
- Volunteers
- 66 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF)
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48…
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
- Trial name
- MACS2030 (NCT01558739)
- Testing
- INC424
- Where
- 10 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi).
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- MANIFEST-2 (NCT04603495)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 156 sites in United States, Australia and 20 more
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Essential Thrombocythemia, Myelofibrosis
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm.
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera
- Trial name
- NCT03878199
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic…
- Trial name
- NCT00638378
- Testing
- Ruxolitinib
- Where
- 15 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells…
- Conditions
- Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01790295
- Testing
- Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- John Mascarenhas
Myelofibrosis
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
The purpose of this study was to investigate the safety, pharmacokinetics and preliminary efficacy of combination treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, rineterkib and NIS793 in…
- Trial name
- ADORE (NCT04097821)
- Testing
- Ruxolitinib, Siremadlin, Crizanlizumab
- Where
- 22 sites in Australia, Canada and 11 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Vitiligo
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
- Trial name
- NCT03099304
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 26 sites in United States
- Volunteers
- 157 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity.
- Trial name
- NCT04414514
- Testing
- Ruxolitinib 1.5% Cream
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Chronic Hand Dermatitis
Topical Ruxolitinib in Chronic Hand Dermatitis
This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD).
- Trial name
- NCT05293717
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- Simplify 1 (NCT01969838)
- Testing
- Momelotinib, Ruxolitinib
- Where
- 114 sites in United States, Australia and 20 more
- Volunteers
- 432 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
- Trial name
- NCT03954236
- Testing
- topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center